DRS

Australian biotech, EnGeneIC, develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response

Retrieved on: 
Wednesday, September 8, 2021

EnGeneIC has commenced a Phase I clinical trial dosing healthy adults at St Vincents Hospital, Melbourne using its patented nanocell technology platform (EDV; EnGeneIC Dream Vector).

Key Points: 
  • EnGeneIC has commenced a Phase I clinical trial dosing healthy adults at St Vincents Hospital, Melbourne using its patented nanocell technology platform (EDV; EnGeneIC Dream Vector).
  • A seminal publication on the preclinical studies is in preparation for a major scientific journal.
  • EnGeneIC is now in Phase 2a clinical trials in patients with intractable cancers, including patients with metastatic pancreatic cancer.
  • EnGeneIC was also featured in theDecember 2019issue ofInsightsCaremagazine as The Top 10 Nanotech Companies to Watch.

National Science Foundation Taps Florida Southern College And LSU To Research Climate Change Impact On Stone Crabs

Retrieved on: 
Wednesday, September 8, 2021

LAKELAND, Fla., Sept. 8, 2021 /PRNewswire/ -- Florida Southern College (FSC) and Louisiana State University (LSU) have been awarded a collaborative grant from the National Science Foundation (NSF) to conduct groundbreaking research on how climate change could impact one of Florida's iconic fisheries, the Florida stone crab. The stone crab fishery is a $30 million commercial industry in Florida and supports over 800 jobs.

Key Points: 
  • LAKELAND, Fla., Sept. 8, 2021 /PRNewswire/ --Florida Southern College (FSC) and Louisiana State University (LSU) have been awarded a collaborative grant from the National Science Foundation (NSF) to conduct groundbreaking research on how climate change could impact one of Florida's iconic fisheries, the Florida stone crab.
  • The stone crab fishery is a $30 million commercial industry in Florida and supports over 800 jobs.
  • Dr. Gravinese and his colleagues at LSU intend to forecast how looming climate changes will affect stone crab populations.
  • Florida Southern has a 14:1 student-to-faculty ratio, is an award-winning national leader in engaged learning, and boasts 30 NCAA Division II National Championships.

Assure Holdings Announces Application for NASDAQ Listing

Retrieved on: 
Friday, September 3, 2021
Transfer, Corporate governance, CUSIP, COVID-19, Securities and Exchange Commission (Nigeria), Coronavirus, Forward-looking statement, Board, SEDAR, Corporation, Compliance, Computershare, NASDAQ, TSX Venture Exchange, Financial compensation, Acquisition, Common stock, Eastern Time Zone, NRS, Professional Football Compensation Committee, OTCQB, TSX, Money transmitter, Letter, Reverse stock split, GLOBE, Nomination, Audit committee, Neurosurgery, Name, Government, News, Common, Compensation, Board of directors, Company, Director, IOM, Awareness, Leonard Farlinger, Shareholder, Risk, Stock, DRS, Hospital, Adoption, Health, Industry, CEO, Employment, Code, Nasdaq, Joint, Overalls, Economy, Audit, Risk management, Security (finance)

DENVER, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (“IONM”), reported that it has submitted an application for listing on the NASDAQ Capital Market (“NASDAQ”), and in connection with the application its Board of Directors approved the following:

Key Points: 
  • DENVER, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), reported that it has submitted an application for listing on the NASDAQ Capital Market (NASDAQ), and in connection with the application its Board of Directors approved the following:
    Adoption of new charters for its Audit Committee, Compensation Committee and Nomination and Corporate Governance Committee to comply with NASDAQ requirements
    The listing of Assures common stock on NASDAQ is subject to satisfaction of the listing requirements of NASDAQ and approval of the listing by the exchange.
  • There can be no assurance that NASDAQ will approve Assures listing application in a timely manner, if at all.
  • We believe that listing our common stock on the NASDAQ is a major step forward for Assure, said John A. Farlinger, Assures executive chairman and CEO.
  • Assures Board of Directors approved a 5:1 share consolidation of its issued and outstanding and authorized common stock to meet the share price requirements of NASDAQ.

HSS Study Could Help Surgeons Improve Mobility Outcomes After Revision Total Knee Arthroplasty

Retrieved on: 
Thursday, September 2, 2021
Magnet, Patient, HSS, U.S. News & World Report, Rheumatology, DRS, Life, Weill Cornell Medicine, Organization, Nursing, Index, Knee, SAN, William H. Harris (orthopaedic surgeon), American Nurses Credentialing Center, Surgeon, Laboratory, Hospital, AAOS, Elective surgery, Doctor of Philosophy, TKA, The Hospital, Physician, Multimedia, University, Man, Woman, Education, University of Ioannina, Infection, Health, Hip, News, Research, American Academy of Orthopaedic Surgeons, American Academy, Hospital for Special Surgery, Long Island, Motion, Therapy, Dentistry, Medical device, Medicine

Stiffness after knee replacement surgery, or total knee arthroplasty (TKA), is a rare but frustrating complication, affecting between 1% and 7% of patients who receive the artificial joints.

Key Points: 
  • Stiffness after knee replacement surgery, or total knee arthroplasty (TKA), is a rare but frustrating complication, affecting between 1% and 7% of patients who receive the artificial joints.
  • Gkiatas, Sculco and their colleagues followed 19 men and women who underwent revision TKA at HSS to try to improve stiffness in patients with prior TKA.
  • All patients gained some mobility after the revision surgery, with the average improvement being approximately 28 degrees of motion.
  • The results of this study provide surgeons with the information needed to educate patients with stiff TKA on expected range of motion outcomes after revision surgery.

U.S. Dermatology Partners is pleased to welcome Dermatologist Umer Ansari, M.D., to their Fairfax, Virginia location

Retrieved on: 
Wednesday, September 1, 2021
Middle East, Friends, History of the University of Maryland, College Park, University, University of Maryland Medical Center, Rosacea, Skin cancer, Partner, Family, Physician, Acne, Eastern Virginia Medical School, American Academy, American Academy of Dermatology, Mohs surgery, Psychology, DRS, Psoriasis, Patient, Mohs, Alpha Omega Alpha, MedStar Washington Hospital Center, Global health, Medical device, Veterinary medicine

FAIRFAX, Va., Sept. 1, 2021 /PRNewswire-PRWeb/ -- U.S Dermatology Partners is pleased to welcome Dermatologist, Dr. Umer Ansari, to their Fairfax, Virginia location.

Key Points: 
  • FAIRFAX, Va., Sept. 1, 2021 /PRNewswire-PRWeb/ -- U.S Dermatology Partners is pleased to welcome Dermatologist, Dr. Umer Ansari, to their Fairfax, Virginia location.
  • Dr. Ansari has presented at national and regional dermatology conferences and has published numerous peer-reviewed articles and chapters for dermatology textbooks.
  • U.S. Dermatology Partners Chief Executive Officer Paul Singh stated, "We are pleased to welcome Dr. Ansari to our thriving Fairfax office.
  • Dr. Ansari treats patients in Fairfax, Virginia, at U.S. Dermatology Partners and is accepting new patients.

Healthcare Industry Leaders Unite Around Patient Safety at Glytec’s Inaugural Conference on Glycemic Innovation and Collaboration

Retrieved on: 
Tuesday, August 31, 2021
Technology, FDA, Diabetes, Health, Pharmaceutical, Practice Management, Research, Software, Infectious Diseases, General Health, Hospitals, Science, Data Management, Nursing, Behavior, Population, Diagnosis, Data visualization, CMS, Prediabetes, Patient safety, Diabetes, Blood, Research, Safety, DRS, Hospital, Target, Mortality, Disease, Patient, Hypoglycemia, Solution, Nursing, LinkedIn, Insulin, FDA, Hyperglycemia, COVID-19, Technology, Medical device, Pharmaceutical industry

Glytec , the only provider of cloud-based insulin management software across the continuum of care, today revealed details about its inaugural conference on glycemic innovation and collaboration, Time to Target: Uniting Around Patient Safety .

Key Points: 
  • Glytec , the only provider of cloud-based insulin management software across the continuum of care, today revealed details about its inaugural conference on glycemic innovation and collaboration, Time to Target: Uniting Around Patient Safety .
  • There is no cost to register for the conference, which will be held virtually on October 26-27, 2021.
  • Healthcare systems have not been incentivized to measure how glycemic management impacts patient safety, and as a result, most hospitals have little to no idea of their rates of severe hypoglycemia or hyperglycemia.
  • Our inaugural conference is a unique opportunity to bring hospital leadership, health care providers and industry leaders together to discuss approaches that will not only improve present-day glycemic management, but also prepare for the next generation of clinical innovation.

NanoString’s GeoMx Digital Spatial Profiling Platform Reveals Insights Into the Immune Landscape of Cancer in Publication in the Journal Cell

Retrieved on: 
Tuesday, August 31, 2021
Research, Technology, Medical Devices, Publishing, Genetics, Communications, Software, Health, Science, Oncology, NanoString Technologies, Massachusetts General Hospital, Interest, Gene, Protein, MIT, Harvard University, Research, RNA, Broad Institute, Cell, DRS, CTA, MicroRNA, Multimedia, Micro-Imaging Dust Analysis System, NASDAQ, DSP, CXCL13, DNA sequencing, Neoplasm, Colorectal cancer, 2021 Essex County Council election, Gene expression, RNA-Seq, 3D printing, Vaccine, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20210831005275/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210831005275/en/
    Image: Current cover of the journal Cell (Graphic: Business Wire)
    The study, Spatially organized multicellular immune hubs in human colorectal cancer, was led by Drs.
  • They used single cell transcriptomics, in situ hybridization, and GeoMx DSP to assess the mechanisms governing interactions between colorectal tumor cells and tumor-infiltrating immune cells.
  • To validate the interaction between malignant and T cell programs, we performed spatially-indexed transcript profiling on our patient tumor sections.
  • The companys GeoMx Digital Spatial Profiler enables highly multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.

Minor Cannabinoids Cell Signaling Research Underway at University of South Carolina, School of Medicine Columbia in collaboration with Precision Plant Molecules

Retrieved on: 
Monday, August 30, 2021
CBC, University, Associate, Cannabinoid, Technology, University of South Carolina, ISCB Senior Scientist Award, CBN, Hormone, School, Science, Neuropathic pain, Research, CB1, PPM, Chemotherapy-induced peripheral neuropathy, CBT, Chemistry, CBDV, DRS, Medical school, Faculty, CBG, THCV, WIN, CB2, CBDA, Management, Fine chemical, Pharmaceutical industry

PPM's science team and University of South Carolina, School of Medicine, have completed initial cell signaling studies examining the interactions of minor cannabinoids and CB1 receptors.

Key Points: 
  • PPM's science team and University of South Carolina, School of Medicine, have completed initial cell signaling studies examining the interactions of minor cannabinoids and CB1 receptors.
  • The minor cannabinoids are produced and purified at PPM using state of the art technology.
  • Kenneth Walsh and Kandy Velazquez, faculty at the University of South Carolina, School of Medicine, oversee the study.
  • Precision Plant Molecules is led by a team of advanced-degreed scientists with pharmaceutical industry and university research backgrounds representing over 100 years of chemistry and plant medicine experience.

Samyang Biopharm USA, Inc. and Spanish National Research Council (CSIC) Announce Strategic Collaboration to Study SYB-010; A First-in-Class, Immune Stimulatory Monoclonal Antibody

Retrieved on: 
Monday, August 30, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Collaboration, LLC, Metastasis, Samyang, European Research Area, Therapy, Spanish National Research Council, Life, European, CISC, Survival, CSIC, Innovation, Ligand, Antibody, Ministry of Science and Innovation (New Zealand), Reyburn, DRS, Biology, NK, Ministry, Â, Patient, General Electric Research Laboratory, Organization, NKG2D, Material, ERA, Fine chemical, Pharmaceutical industry, the Spanish National Research Council, Samyang Biopharm USA, Inc., THE SPANISH NATIONAL RESEARCH COUNCIL, SAMYANG BIOPHARM USA, INC.

Samyang Biopharm USA, Inc. ( https://us.samyangbiopharm.com ) a subsidiary of Samyang Holdings Corp. ( https://samyangbiopharm.com/eng ), announced today that the company has entered into a research collaboration with the Spanish National Research Council (CSIC), a state agency for scientific research and technological development.

Key Points: 
  • Samyang Biopharm USA, Inc. ( https://us.samyangbiopharm.com ) a subsidiary of Samyang Holdings Corp. ( https://samyangbiopharm.com/eng ), announced today that the company has entered into a research collaboration with the Spanish National Research Council (CSIC), a state agency for scientific research and technological development.
  • We look forward to future involvement within this collaboration" said Sean McKenna, Ph.D., Vice President of Research, Samyang Biopharm USA.
  • SYB-010 is a monoclonal antibody targeting the human NKG2D-ligands, MCA/B, which has shown a clear immumodulatory effect in pre-clinical models.
  • The Spanish National Research Council is a state agency for scientific research and technological development.

EXFO Completes Going-Private Transaction and Begins Delisting of Shares from TSX and NASDAQ

Retrieved on: 
Friday, August 27, 2021
Industry, Certification, Toyota Canada Inc., Software, Intention, SEC, Corporation, Leadership, Private Securities Litigation Reform Act, Arrangement, Canada Business Corporations Act, Automation, DRS, Forward-looking statement, EXFO, NASDAQ, Attempted purchase of Time Warner Cable by Comcast, Environment, Solution, TSX, Toronto Stock Exchange, Security (finance)

Pursuant to the Arrangement, the Purchaser acquired all the issued and outstanding subordinate voting shares of EXFO, other than the subordinate voting shares held by the Purchaser, for US $6.25 per subordinate voting share in cash.

Key Points: 
  • Pursuant to the Arrangement, the Purchaser acquired all the issued and outstanding subordinate voting shares of EXFO, other than the subordinate voting shares held by the Purchaser, for US $6.25 per subordinate voting share in cash.
  • "EXFO has built a tremendous reputation as a disruptive innovator and partner of choice with best-of-class support and service on a global basis.
  • EXFO and the Purchaser will effect a vertical short-form amalgamation on or about September 1, 2021, with the Purchaser and EXFO continuing as one corporation under the name "EXFO Inc."
    As a result of the transaction, the subordinate voting shares of EXFO will be voluntarily and imminently de-listed from the Toronto Stock Exchange and the NASDAQ.
  • EXFO develops smarter test, monitoring and analytics solutions for fixed and mobile network operators, webscale companies and equipment manufacturers in the global communications industry.